RPBIF up .13 to.65 on 3 X vol. on today's pr.
Response Biomedical Corporation Receives Notice of Allowance from United States Patent and Trademark Office
Wednesday January 31, 12:52 pm ET
VANCOUVER, Jan. 31 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX-V: RBM, OTCBB: RPBIF) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the patent, entitled "Sensitive Immunochromatographic Assay". This patent covers key aspects of Response Biomedical's lateral flow immunoassays with the RAMP® point-of-care testing platform. The RAMP platform provides highly sensitive and reliable results, typically in less than 15 minutes.
"The Fong Patent is a very important component of our intellectual property in the immunoassay space," said Bill Radvak, President and CEO. "The importance of the RAMP system is that our method of quantitative measurement allows near laboratory analytical performance in a point-of-care environment, thus allowing the clinician to make a critical and immediate diagnosis."
This patent has also been issued in Australia and is pending in Europe, China, Japan, Hong Kong and Canada.
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its portable RAMP Platform for clinical and environmental applications. RAMP represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and for laboratory use. The RAMP System consists of a portable fluorescent Reader and single-use, disposable Test Cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP clinical tests are commercially available for the early detection of heart attack and congestive heart failure. The Company recently filed a submission with the US FDA for market clearance for its NT-proBNP test, expected to be on the US market in 2007. Sales have already commenced in Europe.
The Company also recently announced a strategic alliance with 3M Company to commercialize rapid infectious disease tests. Clinical trials for Staphylococcus aureus and Influenza A/B are now underway, with commercialization expected in 2007.
In the non-clinical market RAMP tests are currently provided for the environmental detection of West Nile virus, and biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. The Company has achieved CE Marking and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.oday's pr. |
